Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: A population-based analysis and validation

被引:0
|
作者
Li, Zi-Hua [1 ]
Zhang, Min-Yue [1 ]
Federico, Massimo [2 ]
Civallero, Monica [2 ]
Manni, Martina [3 ]
Alonso-Alvarez, Sara [4 ]
Hou, Jian [1 ,5 ]
Huang, Hong-Hui [1 ,5 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Hematol, Shanghai, Peoples R China
[2] Univ Modena & Reggio Emilia, Surg Med & Dent Dept, Morphol Sci Related Transplant Oncol & Regenerat M, Dermatol Unit, Modena, Italy
[3] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy
[4] Hosp Univ Cent Asturias, Insituto Invest Sanit Principado Asturias ISPA, Oviedo, Asturias, Spain
[5] 160 Pujian Rd, Shanghai 200127, Peoples R China
关键词
follicular lymphoma; histological transformation; diffuse large B-cell lymphoma; prognosis; population-based study; SINGLE-ARM; 1ST-LINE IMMUNOCHEMOTHERAPY; OPEN-LABEL; RISK; OUTCOMES; MULTICENTER; RITUXIMAB; ERA;
D O I
10.1002/cncr.35378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The histological transformation (HT) of follicular lymphoma (FL) is a crucial biological event. The study aimed to evaluate the incidence, clinicial characteristics, prognosis and impact of HT time on survival of FL transforming to diffuse large B-cell lymphoma in population-based large-scale cohorts. Methods: A retrospective cohort study of FL with HT was performed in the Surveillance, Epidemiology, and End Results database. The Hematological Malignancy Research Network FL cohort and Aristotle study FL cohort were used to assess the external validity. Results: Among 44,127 FL cases from the Surveillance, Epidemiology, and End Results database, 1311 cases were pathology-proven recorded to transform to diffuse large B-cell lymphoma. The cumulative rates of HT at 5, 10, and 15 years after FL diagnosis were estimated to be 1.19%, 2.93%, and 5.01%, respectively. Significantly worse overall survival and cancer-specific survival were exhibited in patients with HT than those without HT. Early HT (transformation of FL within 48 months after FL diagnosis [TOD48]) was an independent predictor for adverse overall survival of HT patients, regardless of treatment modalities before transformation. The adverse prognostic effect of TOD48 was validated in the Hematological Malignancy Research Network cohort and Aristotle study cohort. Older age (>75 years) and B symptoms within FL at diagnosis were the independent risk factors of TOD48. Furthermore, a novel prognostic model combining TOD48 with Follicular Lymphoma International Prognostic Index (TOD48-FLIPI) was constructed and validated for risk stratification. Conclusion: TOD48 was a risk indicator of HT, and the novel prognostic model "TOD48-FLIPI" for HT patients was proposed.
引用
收藏
页码:3321 / 3332
页数:12
相关论文
共 50 条
  • [41] Diffuse large B-cell lymphoma
    Martelli, Maurizio
    Ferreri, Andres J. M.
    Agostinelli, Claudio
    Di Rocco, Alice
    Pfreundschuh, Michael
    Pileri, Stefano A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 87 (02) : 146 - 171
  • [42] Diffuse large B-cell lymphoma: An institutional analysis
    Gogia, Ajay
    Das, Chandan K.
    Kumar, Lalit
    Sharma, Atul
    Tiwari, Akash
    Sharma, M. C.
    Mallick, Soumya
    SOUTH ASIAN JOURNAL OF CANCER, 2018, 7 (03) : 200 - 202
  • [43] ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study
    Wu, Xingchen
    Pertovaara, Hannu
    Dastidar, Prasun
    Vornanen, Martine
    Paavolainen, Lassi
    Marjomaki, Varpu
    Jarvenpaa, Ritva
    Eskola, Hannu
    Kellokumpu-Lehtinen, Pirkko-Liisa
    EUROPEAN JOURNAL OF RADIOLOGY, 2013, 82 (04) : E158 - E164
  • [44] Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
    Tomita, Naoto
    Takasaki, Hirotaka
    Fujisawa, Shin
    Miyashita, Kazuho
    Ogusa, Eriko
    Kishimoto, Kumiko
    Matsuura, Shiro
    Sakai, Rika
    Koharazawa, Hideyuki
    Yamamoto, Wataru
    Fujimaki, Katsumichi
    Fujita, Hiroyuki
    Ishii, Yoshimi
    Taguchi, Jun
    Kuwabara, Hideyuki
    Motomura, Shigeki
    Ishigatsubo, Yoshiaki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2013, 53 (02) : 121 - 125
  • [45] Conditional survival of patients with diffuse large B-cell lymphoma
    Moller, MB
    Pedersen, NT
    Christensen, BE
    CANCER, 2006, 106 (10) : 2165 - 2170
  • [46] Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China
    Xiong, Yu
    Liu, Weicheng
    Chen, Xiaoping
    Mo, Pingzheng
    Xiong, Yong
    Deng, Liping
    Zhang, Yongxi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [47] Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma
    Boonstra, R
    Bosga-Bouwer, A
    Mastik, M
    Haralambieva, E
    Conradie, J
    van den Berg, E
    van den Berg, A
    Poppema, S
    HUMAN PATHOLOGY, 2003, 34 (09) : 915 - 923
  • [48] A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma
    A J Davies
    A M Lee
    C Taylor
    A J Clear
    L K Goff
    S Iqbal
    D Cuthbert-Heavens
    M Calaminici
    A J Norton
    T A Lister
    J Fitzgibbon
    Leukemia, 2005, 19 : 1459 - 1465
  • [49] Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma
    Tada, Kohei
    Kim, Sung-Won
    Asakura, Yoshitaka
    Hiramoto, Nobuhiro
    Yakushijin, Kimikazu
    Kurosawa, Saiko
    Tajima, Kinuko
    Mori, Shin-ichiro
    Heike, Yuji
    Tanosaki, Ryuji
    Maeshima, Akiko Miyagi
    Taniguchi, Hirokazu
    Furuta, Koh
    Kagami, Yoshikazu
    Matsuno, Yoshihiro
    Tobinai, Kensei
    Takaue, Yoichi
    Fukuda, Takahiro
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (08) : 770 - 775
  • [50] A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
    Chung, Clement
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2022, 12 : 99 - 106